Résumé Les carcinomes urothéliaux d'origine vésicale sont des tumeurs particulièrement
agressives avec un fort potentiel métastatique. Leur pronostic a très peu évolué sur les …

Accounting for 14,000 deaths in the USA last year, research informs us that advanced
bladder cancer is a lethal disease with a median survival that has remained a little over 1 …

Purpose Intravenous vinflunine 320 mg/m 2 every 3 weeks plus best supportive care
resulted in better overall survival in comparison with best supportive care alone for eligible …

Objective: The objective of this retrospective study was to investigate the efficacy and safety
of vinflunine monotherapy and the utility of second-line prognostic factors in patients with …

Background To retrospectively assess the efficacy and safety of Vinflunine (VFL) under
routine conditions and identify overall survival (OS) prognostic factors. Methods Twenty …

Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and
the United States. For locally advanced or metastatic disease, there are two standard firstline …

Résumé Le cancer urothélial métastatique ou localement avancé demeure une maladie très
grave. Labase de sa prise en charge repose sur la chimiothérapie systémique. En 30ans …

Background: A systematic review and meta-analysis of the use of systemic vinflunine (VIN)
in the treatment of urothelial carcinoma (UC) was performed to evaluate its efficacy based on …

Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and
advanced urothelial cancer after failure of platin-containing therapy. Since approval, the …

Background Vinflunine is recommended in the European guideline for the treatment of
advanced or metastatic urothelial cell carcinoma (UCC) after failure of platinum-based …